Nantahala Capital Management’s Eloxx Pharmaceuticals ELOX Stock Holding History

Nantahala Capital Management’s Portfolio ELOX Stock Details ELOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.55M	Buy	+400,000	New	+$5.1M	0.18%	102

Other funds holding ELOX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SGM

Seven Grand Managers Bronxville, New York $2.48B AUM 65.09% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Nantahala Capital Management's ELOX Position: Q2 2026 in Review

Nantahala Capital Management opened a new position in Eloxx Pharmaceuticals (ELOX) in Q2 2026: 400,000 shares worth $5.55M. The stake represents 0.18% of the portfolio and ranks #102 among its holdings.

20 funds tracked by Wall St. Rank hold ELOX as of Q2 2026.

Nantahala Capital Management held 400,000 shares of Eloxx Pharmaceuticals worth $5.55M as of Q2 2026.
Eloxx Pharmaceuticals was a new Nantahala Capital Management position in Q2 2026.
Eloxx Pharmaceuticals made up 0.18% of Nantahala Capital Management's portfolio in Q2 2026, its #102 holding.
20 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.